Revenues from the Thoratec product line, the PVAD and IVAD were $6.1 million versus $7.2 million a year ago or a decrease of 15%.
We experienced solid year-over-year unit growth in the quarter selling 917 pumps, an increase of 10% versus 836 pumps in the fourth quarter a year ago. Unit growth was driven by a 13% increase in HeartMate offset by a mid-teens decline in PVAD and IVAD units.
In the U.S. market, we shipped 704 pumps representing a strong 15% increase over 613 pumps a year ago. Internationally, we faced a notably challenging comparison and pump units declined 4% year-over-year from 223 in the fourth quarter of 2010 to 213 in the fourth quarter of 2011.
I should note though that the international decline was driven solely by the PVAD and IVAD franchise, while the HeartMate II franchise grew 8% despite the tough comparison in distributor markets. In fact, excluding European distributor territories international HeartMate II unit growth was 18% for the quarter and 17% for the full year.Read the rest of this transcript for free on seekingalpha.com